1 / 62

CARCINOMA DELLA PROSTATA

CARCINOMA DELLA PROSTATA. PROSTATE CANCER. Prostate Anatomy. Prostate cancer is a disease predominantly of the older male population. Autopsy series have indicated that 15% to 30% of men older than the age 50 years have histologic evidence of prostate cancer. PROSTATE CANCER DEATHS BY AGE.

meryle
Télécharger la présentation

CARCINOMA DELLA PROSTATA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CARCINOMA DELLA PROSTATA

  2. PROSTATE CANCER Prostate Anatomy

  3. Prostate cancer is a disease predominantly of the older male population. Autopsy series have indicated that 15% to 30% of men older than the age 50 years have histologic evidence of prostate cancer

  4. PROSTATE CANCER DEATHS BY AGE

  5. Risk Factors for Prostate Cancer • Age – Found mainly in men over age 55. Average age of diagnosis is 70 • Family History – Men’s risk is higher if father or brother is diagnosed before the age of 60 • Race – Prostate cancer is found more often in African American men then White men. It is less common in Asian and American Indian men • Dietary factors – Evidence suggests that a diet high in fat may increase the risk of prostate cancer and diets high in fruits and vegetables decrease the risk

  6. Risk for Developing Prostate Cancer

  7. Genetic alterations associated with progression of prostate cancer

  8. Hypothalamus pituitary testicular axis

  9. Detailed schematic: Lateral section of a normal prostate

  10. PROSTATE CANCER Stage A : Deep tumor: may not be detected by digital-rectal exam Stage B: Tumor may be detected by DRE or ultrasound Stage C: Spread to surrounding tissue Stage D: Metastasis to bone and lymph nodes

  11. The Gleason scoring system for prostate cancer. The Gleason grading system is used to evaluate or grade prostate cancer cells obtained by needle biopsy. The cells are assigned a number between 1 and 5 nearly normal cells are grade 1, and the most abnormal are grade 5. The scores of the two most common cell patterns are added together. Gleason scores range from 2 to 10. The higher the grade, the more aggressive the cancer.

  12. Prostatic Intraepithelial Neoplasia • 85% carcinomas have associated PIN • High grade PIN has 30-50% risk of CA on subsequent biopsies cf 13% in controls • PIN does not cause elevated PSA • Atypical foci in 3-5% of biopsies, 50% risk of cancer on repeat biopsy

  13. Symptoms of Prostate Cancer • Frequent urination • Inability to urinate • Trouble starting and stopping urination • Blood in the urine or semen • Painful ejaculation • Painful or burning urination

  14. Screening for Prostate Cancer • Prostate-Specific Antigen Blood Test (PSA) –Measures substance made by the prostate gland • Digital Rectal Exam (DRE) –Physical exam of the Prostate Gland • Transrectal Ultrasound (TRUS) – Uses sound waves to make an image of the prostate on a video screen

  15. Organ confined prostate cancer is curable Advanced prostate cancer is incurable Screening offers earlier diagnosis Early detection is our only hope for mortality reduction More men die with Prostate cancer than of it PSA test not accurate enough Biopsy and treatment may cause morbidity No trial to show mortality reduction Screening … For & Against

  16. Factors Increasing PSA • Cycling • Prostate massage • Cystoscopy • Ejaculation • Prostate biopsy • Transrectal Ultrasound • Prostate disease

  17. Percentage risk of CaP

  18. Screening - Improving the PSA • PSA Velocity > 0.75 ng/ml/yr • PSA Density • Age adjusted PSA • Molecular forms- free / total PSA

  19. PSA Isoforms • Free and complexed PSA - ACT • FREE / TOTAL ratio < 10% suggestive • Complex now measurable

  20. Digital Rectal Exam for Prostate Tumors

  21. Transrectal ultrasound-guided biopsy of the prostate

  22. Management Alternatives • Expectant -- Watchful Waiting • Radical Prostatectomy • Radiation Therapy -- EBRT, 3D - CRT, Brachytherapy: HDR, Seed • Hormonal -- Mono Rx, MAB • Combination

  23. Trans-urethral Resection

  24. Prostate CancerTreatment Paradigms Relapsed and Newly diagnosed M+ Hormone Refractory Clinically Localized Local treatment Endocrine Chemotherapy

  25. Prostate Cancer Treatment Background • 50% fail after local treatment • 10-15% have distant metastasis at presentation • Virtually all progress after endocrine treatment • Chemotherapy used for symptomatic control • No survival advantage in phase-III trials

  26. Endocrine control of prostate cancer

  27. Strategies for Androgen Deprivation LHRH = Luteinizing hormone-releasing hormone LH = Luteinizing hormone T = Testosterone 5 R = 5-alpha reductase. DHT = Dihydrotestosterone. AR = Androgen receptor

  28. Types of Androgen Deprivation

  29. Side Effects of Androgen Deprivation

  30. Adjuvant trials. SWOG 9921: adjuvant androgen deprivation versus mitoxantrone plus prednisone plus androgen deprivation in selected high-risk prostate cancer patients following radical prostatectomy, phase III. Prior neoadjuvant therapy is permitted if the duration is 4 months or less and if clinical criteria (PSA15 ng/mL or biopsy GS 7 or PSA 10 ng/mL and GS 6) are satisfied prior to surgery.

  31. Adjuvant trials. RTOG 99-02: phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide for localized high-risk prostate cancer.

  32. Adjuvant hormonal therapy. Survival improvements were noted only in one trial conducted by the European Organization for Research and Treatment of Cancer with the use of adjuvant hormonal therapy. (Adapted from Bolla et al.)

  33. Adjuvant hormones. Adjuvant hormones after radical prostatectomy have demonstrated survival enhancement in patients with pathologically positive lymph nodes. (Adapted from Messing et al.

  34. SWOG Intergroup 0162 trial of continuous versus intermittent androgen deprivation

  35. Hormone-independent prostate cancer. The development of hormonal escape is depicted. Despite a high initial response rate to androgen deprivation, essentially all men will fail and progress to androgen independence and ultimately hormone refractory status. Treatment for patients with hormone-refractory prostate cancer must be tailored individually, and take into account the need to maintain quality of life in this terminal stage of the disease. Antiandrogen withdrawal, second-line hormonal therapy, palliative supportive care measures including radiation therapy (external or systemic) and pain control, and chemotherapy are all valid options.

  36. Mitoxantrone + Steroids Versus Steroids Alone Table of randomized chemotherapy trials in metastatic disease. Although chemotherapy has not demonstrated an impact on survival yet, the use of mitoxantrone and steroids has, however, demonstrated a significant palliative effect in randomized trials

  37. SWOG trial of chemotherapy in metastatic disease. SWOG Intergroup 9916 randomized phase III study of docetaxel + estramustine versus mitoxantrone + prednisone in patients with hormone-refractory prostate cancer; 620 patients must be entered to detect a 33% survival difference. Future directions include exploring biologic therapies such as epithelial growth factor receptor inhibitors and antiangiogenesis strategies.

  38. Combined Androgen Deprivation Compared with Monotherapy in Advanced Prostate Cancer

  39. Docetaxel in HRPC • Multiple phase II studies • Responses in 45-82% (similar 95% CI duration) • Estramustine based RR higher but more toxic • Single agent data (weekly and every 3 wks) consistently safe and effective • Superior to mitoxantrone + prednisone?

  40. TAX327 Study Design Docetaxel 75 mg/m2 q3 wks + Prednisone 5 mg bid Stratification Pain level PPI ≥ 2 or AS ≥ 10 vs. PPI < 2 or AS < 10 KPS ≤ 70 vs. ≥ 80 R A N D O M I Z E Docetaxel 30 mg/m2 wkly 5 of 6 wks +Prednisone 5 mg bid Mitoxantrone 12 mg/m2 q3 wks + Prednisone 5 mg bid Treatment duration in all 3 arms = 30 wks

More Related